Red blood cell-derived nanovesicles for safe and efficient macrophage-targeted drug delivery in vivo

2019 ◽  
Vol 7 (1) ◽  
pp. 187-195 ◽  
Author(s):  
Xue Wan ◽  
Shi Zhang ◽  
Feng Wang ◽  
Wei Fan ◽  
Chenxi Wu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Targeted Drug Delivery ◽  
Drug Carriers ◽  
Hydrophilic Drug ◽  
Targeted Drug

RBC-derived nanovesicles are effective hydrophilic drug carriers and can effectively deliver drugs into macrophages both in vitro and in vivo.

Transferrin Modified Graphene Oxide for Glioma-Targeted Drug Delivery: In Vitro and in Vivo Evaluations

2013 ◽  
Vol 5 (15) ◽  
pp. 6909-6914 ◽  
Author(s):  
Guodong Liu ◽  
He Shen ◽  
Jinning Mao ◽  
Liming Zhang ◽  
Zhen Jiang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Graphene Oxide ◽  
Targeted Drug Delivery ◽  
Modified Graphene Oxide ◽  
Targeted Drug ◽  
Modified Graphene

scholarly journals Niosomes: A Novel Targeted Drug Delivery System

2021 ◽  
Author(s):  
Iman Akbarzadeh ◽  
Kamand Sedaghatnia ◽  
Mahsa Bourbour ◽  
Zahra Moghaddam ◽  
Maryam Moghtaderi ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
In Silico ◽  
Metallic Nanoparticles ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Structure Characterization ◽  
Targeted Drug

Nanotechnology is making significant transformation to our world, especially in healthcare and the treatment of diseases. It is widely used in different medical applications, such as in treatment and detection. Targeting diseased cell with nanomedicines is one of the numerous applications of nanotechnology. Targeted drug delivery systems for delivering various types of drugs to specific sites are such a dynamic area in pharmaceutical biotechnology and nanotechnology. Compared to conventional drugs, nanomedicines have a higher absorption and bioavailability rate, improving efficacy and minimizing side effects. There are several drug delivery systems including metallic nanoparticles, polymers, liposomes, and microspheres, but one of the most important is the niosomes, which are produced by nonionic surfactants. Because of the amphiphilic nature and structure, hydrophilic or hydrophobic drugs can be loaded into niosome structures. Other compounds, including cholesterol, can also be applied to the niosomes' backbone to rigidize the structure. Several variables such as the type of surfactant in niosome production, the preparation method, and the hydration temperature can affect the structure of the niosomes. Nevertheless, in-silico design of drug delivery formulations requires molecular dynamic simulation tools, molecular docking, and ADME (absorption; distribution; excretion; metabolism) properties, which evaluate physicochemical features of formulation and ADME attitudes before synthesis, investigating the interaction between nano-carriers and specific targets. Hence, experimenting in-vitro and in-vivo is essential. In this review, the basic aspects of niosomes are described including their structure, characterization, preparation methods, optimization with in-silico tools, factors affecting their formation, and limitations.

scholarly journals Micro/Nanorobot: A Promising Targeted Drug Delivery System

Pharmaceutics ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 665 ◽  
Author(s):  
Mengyi Hu ◽  
Xuemei Ge ◽  
Xuan Chen ◽  
Wenwei Mao ◽  
Xiuping Qian ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Electric Fields ◽  
Targeted Drug Delivery ◽  
Disease Diagnosis ◽  
Research Field ◽  
Traditional Drug ◽  
Targeted Drug ◽  
Autonomous Movement

Micro/nanorobot, as a research field, has attracted interest in recent years. It has great potential in medical treatment, as it can be applied in targeted drug delivery, surgical operation, disease diagnosis, etc. Differently from traditional drug delivery, which relies on blood circulation to reach the target, the designed micro/nanorobots can move autonomously, which makes it possible to deliver drugs to the hard-to-reach areas. Micro/nanorobots were driven by exogenous power (magnetic fields, light energy, acoustic fields, electric fields, etc.) or endogenous power (chemical reaction energy). Cell-based micro/nanorobots and DNA origami without autonomous movement ability were also introduced in this article. Although micro/nanorobots have excellent prospects, the current research is mainly based on in vitro experiments; in vivo research is still in its infancy. Further biological experiments are required to verify in vivo drug delivery effects of micro/nanorobots. This paper mainly discusses the research status, challenges, and future development of micro/nanorobots.

scholarly journals Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells

Pharmaceutics ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 92
Author(s):  
Shen Cheng ◽  
Susheel Kumar Nethi ◽  
Mahmoud Al-Kofahi ◽  
Swayam Prabha
Keyword(s):  
Drug Delivery ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Targeted Drug Delivery ◽  
Quantitative Description ◽  
In Vivo Studies ◽  
Pharmacodynamic Modeling ◽  
Targeted Drug

Nano-engineered mesenchymal stem cells (nano-MSCs) are promising targeted drug delivery platforms for treating solid tumors. MSCs engineered with paclitaxel (PTX) loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) are efficacious in treating lung and ovarian tumors in mouse models. The quantitative description of pharmacokinetics (PK) and pharmacodynamics (PD) of nano-MSCs is crucial for optimizing their therapeutic efficacy and clinical translatability. However, successful translation of nano-MSCs is challenging due to their complex composition and physiological mechanisms regulating their pharmacokinetic-pharmacodynamic relationship (PK–PD). Therefore, in this study, a mechanism-based preclinical PK–PD model was developed to characterize the PK–PD relationship of nano-MSCs in orthotopic A549 human lung tumors in SCID Beige mice. The developed model leveraged literature information on diffusivity and permeability of PTX and PLGA NPs, PTX release from PLGA NPs, exocytosis of NPs from MSCs as well as PK and PD profiles of nano-MSCs from previous in vitro and in vivo studies. The developed PK–PD model closely captured the reported tumor growth in animals receiving no treatment, PTX solution, PTX-PLGA NPs and nano-MSCs. Model simulations suggest that increasing the dosage of nano-MSCs and/or reducing the rate of PTX-PLGA NPs exocytosis from MSCs could result in improved anti-tumor efficacy in preclinical settings.

Sign in / Sign up

Export Citation Format

Share Document